EMA-EP regimen, as firstline multiple agent chemotherapy in high-risk GTT patients (stage II-IV)
Authors:
- 1 March 2004
- journal article
- clinical trial
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 14 (2) , 360-365
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Clinical Characteristics of Gestational Trophoblastic Disease at A Single Institute.The Tohoku Journal of Experimental Medicine, 2002
- The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assessmentInternational Journal of Gynecological Cancer, 2001
- Guidelines for the Stratification of Patients Recruited to Trials of Therapy for Low-Risk Gestational Trophoblastic TumorGynecologic Oncology, 2000
- Etoposide and Cisplatin/Etoposide, Methotrexate, and Actinomycin D (EMA) Chemotherapy for Patients With High-Risk Gestational Trophoblastic Tumors Refractory to EMA/Cyclophosphamide and Vincristine Chemotherapy and Patients Presenting With Metastatic Placental Site Trophoblastic TumorsJournal of Clinical Oncology, 2000
- Effects of multiagent chemotherapy and independent risk factors in the treatment of high‐risk GTT —25 years experiences of KRI‐TRDInternational Journal of Gynecology & Obstetrics, 1998
- Remission of refractory gestational trophoblastic disease with high-dose paclitaxelAnti-Cancer Drugs, 1996
- Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989BJOG: An International Journal of Obstetrics & Gynaecology, 1991
- EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT)Gynecologic Oncology, 1988
- Developments in chemotherapy for medium‐ and high‐risk patients with gestational trophoblastic tumours (1979–1984)BJOG: An International Journal of Obstetrics & Gynaecology, 1986